Ginette 35: Comprehensive Hormonal Therapy for Women
Ginette-35
| Product dosage: 2.035mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 42 | 2.20 $ | 92.43 $ (0%) | 🛒 Add to cart |
| 63 | 2.06 $ | 138.64 $ 129.87 $ (6%) | 🛒 Add to cart |
| 84 | 1.98 $ | 184.86 $ 166.14 $ (10%) | 🛒 Add to cart |
| 126 | 1.92 $ | 277.29 $ 242.19 $ (13%) | 🛒 Add to cart |
| 168 | 1.87 $
Best per pill | 369.72 $ 314.73 $ (15%) | 🛒 Add to cart |
Synonyms | |||
Ginette 35 is a prescription medication combining cyproterone acetate and ethinylestradiol, designed specifically for the management of androgen-related conditions in women. It is primarily indicated for the treatment of moderate to severe acne, hirsutism, and androgenetic alopecia in women of reproductive age, particularly when topical treatments or other antiandrogen therapies have proven insufficient. This product card provides a detailed, expert-level overview of its features, benefits, usage, and safety considerations to support informed medical decision-making.
Features
- Contains 2 mg cyproterone acetate and 0.035 mg ethinylestradiol per tablet
- Packaged in a calendar blister of 21 active tablets
- Oral administration; film-coated for ease of swallowing
- Requires prescription and medical supervision
- Manufactured under strict pharmaceutical quality standards
Benefits
- Effectively reduces sebum production and improves moderate to severe acne lesions
- Diminishes unwanted facial and body hair growth (hirsutism) by counteracting androgen effects
- Helps stabilize or reduce hair loss associated with female pattern androgenetic alopecia
- Provides reliable contraception when taken as directed
- Regulates menstrual cycles and may reduce symptoms of premenstrual syndrome in some users
- Offers a dual-action hormonal approach for comprehensive dermatological and endocrine management
Common use
Ginette 35 is commonly prescribed for women presenting with signs of hyperandrogenism, such as persistent acne vulgaris unresponsive to conventional therapies, mild to moderate hirsutism, or female pattern hair loss. It is also utilized off-label in certain cases of polycystic ovary syndrome (PCOS) to manage dermatological symptoms and regulate menstrual cycles. Treatment is typically initiated in women who also desire oral contraception.
Dosage and direction
The standard dosage is one tablet daily for 21 consecutive days, followed by a 7-day tablet-free interval, during which withdrawal bleeding usually occurs. Tablets should be taken at approximately the same time each day, with water, and can be taken with or without food. Treatment cycles are repeated continuously. Initiation should align with menstrual cycle timing as per prescribing guidelines or physician instruction.
Precautions
- Not intended for use during pregnancy or lactation
- Requires assessment of cardiovascular risk factors prior to and during therapy
- Monitoring of liver function, blood pressure, and metabolic parameters recommended
- Caution advised in patients with a history of depression, migraines, or thromboembolic disorders
- May affect glucose tolerance; diabetic patients should be monitored closely
- Discontinue use 4 weeks before elective surgery or periods of prolonged immobilization
Contraindications
- History of or current venous or arterial thrombosis/thromboembolism
- Known or suspected hormone-dependent malignancies
- Severe hepatic disease or history of hepatic tumors
- Undiagnosed abnormal genital bleeding
- Hypersensitivity to any component of Ginette 35
- Pancreatitis or severe hypertriglyceridemia
Possible side effects
Common side effects may include nausea, headache, breast tenderness, mood changes, and breakthrough bleeding, especially during initial cycles. Less frequently, weight changes, decreased libido, chloasma, or contact lens intolerance may occur. Serious but rare adverse effects include venous thromboembolism, hypertension, hepatic disorders, and gallbladder disease. Patients should report persistent or severe symptoms promptly.
Drug interaction
Ginette 35 may interact with enzyme-inducing drugs (e.g., rifampicin, certain anticonvulsants, St. John’s wort), reducing efficacy. Broad-spectrum antibiotics may temporarily decrease contraceptive reliability. Concurrent use with other hormonal therapies is not recommended. Consult a full prescribing information or pharmacist for specific drug interaction guidance.
Missed dose
If a tablet is missed and less than 12 hours have passed, take it immediately and continue the schedule. If more than 12 hours have passed, refer to package instructions regarding additional contraceptive precautions. Consistently missed doses may reduce efficacy for both dermatological and contraceptive outcomes.
Overdose
Serious toxicity from overdose is unlikely, but nausea, vomiting, or withdrawal bleeding may occur. Symptomatic treatment is advised. There is no specific antidote. Medical attention should be sought in cases of accidental ingestion by children or large intentional overdose.
Storage
Store below 25°C in a dry place, protected from light. Keep out of reach of children. Do not use after the expiration date printed on the packaging.
Disclaimer
This information is intended for healthcare professionals and should not replace personalized medical advice. Always consult a qualified physician for diagnosis, treatment decisions, and individualized dosing. Use strictly as prescribed.
Reviews
Clinical studies and patient reports generally indicate high satisfaction with Ginette 35 for improving acne and hirsutism, with noticeable results often within 3–6 months. Some users report initial side effects that typically subside. Long-term adherence is favorable when monitored appropriately. Individual experiences may vary.